Form 4: Director Adrienne Graves Receives Ocular Therapeutix Equity

Director Adrienne L. Graves was granted 14,000 restricted stock units and 44,000 stock options by Ocular Therapeutix, Inc.

Summary

• Director Adrienne L. Graves received a grant of 14,000 restricted stock units (RSUs) on June 10, 2026.
• The director was also granted 44,000 stock options with an exercise price of $8.74 per share.
• Both the RSUs and stock options are subject to a one-year vesting schedule tied to continued board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standard retention mechanism for board members.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Potential for future dilution if additional equity incentives are issued to board members or employees.

Future Outlook

The equity grants vest on the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, whichever is earlier, contingent upon continued board service.

Management Comments

• The grants were issued under the company's 2021 Stock Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure director alignment with company performance.

Comparison to Industry Standards

• The use of a one-year vesting period for director equity is consistent with standard practices for mid-cap biotechnology firms.
• The grant size is typical for non-executive director compensation packages in the industry.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of RSUs and options on June 10, 2027, or the date of the next annual meeting.

Key Dates

Keywords

Ocular Therapeutix, OCUL, Form 4, Insider Trading, Equity Compensation, Director Compensation